Literature DB >> 23266582

Risk of occult irresectable disease at liver resection for hepatic colorectal cancer metastases: a contemporary analysis.

Kai A Bickenbach1, Ronald P Dematteo, Yuman Fong, T Peter Kingham, Peter J Allen, William R Jarnagin, Michael I D'Angelica.   

Abstract

INTRODUCTION: Traditionally, rates of irresectable disease at laparotomy for colorectal liver metastases (CRLM) have ranged from 15 to 70%. Diagnostic laparoscopy has been shown to be effective at preventing nontherapeutic laparotomy in selected patients. The purpose of this study was to analyze the resectability rate and role of diagnostic laparoscopy in a contemporary cohort.
METHODS: Using a prospectively maintained database, we identified patients who were explored for presumed resectable CRLM. Clinical and pathologic data associated with the finding of irresectable disease were analyzed.
RESULTS: From 2008-2010, 455 patients were explored. Of these, 35 (7.7%) did not undergo a resection and/or ablation. Of the 35 patients with irresectable disease, 15 (43%) had disease limited to the liver, 17 (49%) had extrahepatic disease (EHD), and 3 (9%) had other reasons precluding resection. Of the whole cohort, 45 patients (9.9%) were found to have EHD, and 27 of these (60%) underwent complete resection or ablation. The only factor associated with irresectable disease was a prior history of EHD, which was present in 29% of those found irresectable versus 13% of those resected (p = 0.022). Diagnostic laparoscopy was performed in 55 patients. Four of these patients had irresectable disease, and three were spared unnecessary laparotomy. Therefore, the yield was 5% and the sensitivity 75%.
CONCLUSIONS: The finding of irresectable disease is a rare event with modern radiologic assessment and the expansion of indications for resection. Diagnostic laparoscopy has a low yield and should be considered if there is a history of EHD or suspicious findings on preoperative imaging.

Entities:  

Mesh:

Year:  2012        PMID: 23266582     DOI: 10.1245/s10434-012-2813-5

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  4 in total

Review 1.  Hepatic arterial infusional chemotherapy in the management of colorectal cancer liver metastases.

Authors:  Alexandre Doussot; Nancy E Kemeny; Michael I D'Angelica
Journal:  Hepat Oncol       Date:  2015-07-27

2.  Complex Surgical Strategies to Improve Resectability in Borderline-Resectable Disease.

Authors:  Motaz Qadan; Michael I D'Angelica
Journal:  Curr Colorectal Cancer Rep       Date:  2015-08-18

3.  First clinical experience of intra-operative high intensity focused ultrasound in patients with colorectal liver metastases: a phase I-IIa study.

Authors:  Aurélien Dupré; David Melodelima; David Pérol; Yao Chen; Jérémy Vincenot; Jean-Yves Chapelon; Michel Rivoire
Journal:  PLoS One       Date:  2015-02-26       Impact factor: 3.240

4.  Thermal ablation of colorectal liver metastases: a position paper by an international panel of ablation experts, The Interventional Oncology Sans Frontières meeting 2013.

Authors:  Alice Gillams; Nahum Goldberg; Muneeb Ahmed; Reto Bale; David Breen; Matthew Callstrom; Min Hua Chen; Byung Ihn Choi; Thierry de Baere; Damian Dupuy; Afshin Gangi; Debra Gervais; Thomas Helmberger; Ernst-Michael Jung; Fred Lee; Riccardo Lencioni; Ping Liang; Tito Livraghi; David Lu; Franca Meloni; Philippe Pereira; Fabio Piscaglia; Hyunchul Rhim; Riad Salem; Constantinos Sofocleous; Stephen B Solomon; Michael Soulen; Masatoshi Tanaka; Thomas Vogl; Brad Wood; Luigi Solbiati
Journal:  Eur Radiol       Date:  2015-05-22       Impact factor: 5.315

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.